Cash Equivalents - Glenmark Life Sciences Ltd (NSE:GLS) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 836.25 INR 0.63%

Updated:

Glenmark Life Sciences Ltd
Cash Equivalents

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

|

Adjust for Inflation

Glenmark Life Sciences Ltd
Cash Equivalents Peer Comparison

DRREDDY

CIPLA

SUNPHARMA

ZYDUSLIFE

T

TORNTPHARM

Company		Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
G	Glenmark Life Sciences Ltd NSE:GLS	Cash Equivalents ₹2.3B	CAGR 3-Years 25%	CAGR 5-Years 157%	CAGR 10-Years N/A
	Dr Reddy's Laboratories Ltd NSE:DRREDDY	Cash Equivalents ₹7.1B	CAGR 3-Years -22%	CAGR 5-Years 26%	CAGR 10-Years N/A
	Cipla Ltd NSE:CIPLA	Cash Equivalents ₹8.7B	CAGR 3-Years -15%	CAGR 5-Years 7%	CAGR 10-Years 17%
	Sun Pharmaceutical Industries Ltd NSE:SUNPHARMA	Cash Equivalents ₹72.2B	CAGR 3-Years 11%	CAGR 5-Years -6%	CAGR 10-Years 1%
	Zydus Lifesciences Ltd NSE:ZYDUSLIFE	Cash Equivalents ₹6.9B	CAGR 3-Years 1%	CAGR 5-Years 10%	CAGR 10-Years 2%
T	Torrent Pharmaceuticals Ltd NSE:TORNTPHARM	Cash Equivalents ₹5.6B	CAGR 3-Years 6%	CAGR 5-Years -11%	CAGR 10-Years -4%

See Also

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cash Equivalents amounts to 2.3B INR.

Over the last year, the Cash Equivalents growth was 0%. The average annual Cash Equivalents growth rates for Glenmark Life Sciences Ltd have been 25% over the past three years , 157% over the past five years .

Join more than 142,600+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.